1. Characterizing Virological Suppression in Today's Treatment Paradigm

2. Key Objectives of This Program

3. Virological Suppression Represents Success for the Patient

4. Definitions of Virological Suppression

5. What Constitutes Virological Failure?

6. How Can We Limit Virological Failure?

7. How Do We Define Success With Highly Efficacious Treatment?

8. Defining Success in Treatment-Naive Patients

9. GEMINI-1 and -2 Phase 3 Study Designs

10. GEMINI-1 and -2 Phase 3 Primary Outcomes

11. GEMINI-1 and -2: Analysis of Participants With TND Over Baseline VL for 2DR and 3DR

12. Considerations for Clinicians

13. FLAIR: Long-Acting Cabotegravir + Rilpivirine for HIV Maintenance

14. FLAIR: Results for Primary and Secondary Endpoints

15. FLAIR: Injection Site Reactions

16. FLAIR: Patient Preference Survey

17. FLAIR: Patients Who Experienced Virologic Failure CAB LA + RPV LA Arm

18. Clinical Case: 48-Year-Old Man

19. Clinical Case: 48-Year-Old Man (cont)

20. Clinical Case: 48-Year-Old Man (cont)

21. Considerations for Clinicians (cont)

22. Clinical Case: 46-Year-Old Woman

23. Clinical Case: 46-Year-Old Woman (cont)

24. SWORD-1 and -2: Analysis of Viral Replication for 2DR vs 3DR

25. Clinical Case: 46-Year-Old Woman (cont)

26. PARTNER Study

27. PARTNER: Key Conclusions

28. Communicating With Patients Regarding Virological Suppression

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)